SULLIVAN CHRISTOPHER RYAN (Interim CFO) sold 99.1% of their position (47K shares) of AVALO THERAPEUTICS, INC. on the open market
Open‑market sale worth $948.7K — a major position exit. Review remaining holdings and any 10b5‑1 plan disclosures.
Common Stock
Shares
+47K
Price / share
$8.04
Trade value
$377.88K
% of position
Common Stock
Shares
−13.83K
Price / share
$18.55
Trade value
$256.66K
% of position
Common Stock
Shares
−12.35K
Price / share
$19.28
Trade value
$238.09K
% of position
Common Stock
Shares
−2.70K
Price / share
$20.76
Trade value
$56.05K
% of position
Common Stock
Shares
−9.22K
Price / share
$21.37
Trade value
$197.01K
% of position
Common Stock
Shares
−8.90K
Price / share
$22.57
Trade value
$200.91K
% of position
Net shares
+0.00
Net value
-$570.84K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 5/6/2026 | M · Option Exercise | +47K | $8.04 | $377.88K | 11111.1% | 423.00 | 47.42K |
| Common Stock Direct | 5/6/2026 | S · Sale | −13.83K | $18.55 | $256.66K | 29.2% | 47.42K | 33.59K |
| Common Stock Direct | 5/6/2026 | S · Sale | −12.35K | $19.28 | $238.09K | 36.8% | 33.59K | 21.24K |
| Common Stock Direct | 5/6/2026 | S · Sale | −2.70K | $20.76 | $56.05K | 12.7% | 21.24K | 18.54K |
| Common Stock Direct | 5/6/2026 | S · Sale | −9.22K | $21.37 | $197.01K | 49.7% | 18.54K | 9.32K |
| Common Stock Direct | 5/6/2026 | S · Sale | −8.90K | $22.57 | $200.91K | 95.5% | 9.32K | 423.00 |
| Total | +0.00 | -$570.84K | ||||||
Stock Option (Right to Buy)
Common Stock
47K shares
Shares
−47K
Strike price
8.04
Held after
116K
Exercisable
—
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) Direct | Common Stock47K shares | 5/6/2026 | M · Option Exercise | −47K | 8.04 | — | 116K |